Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 85Recurrence 10Lymphoma 8Leukemia, Myeloid, Acute 6Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Plasmacytoma 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Amyloidosis 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1

Interventions

Cytarabine 72Etoposide 29Daunorubicin 25Filgrastim 24Idarubicin 22Mitoxantrone 21Busulfan 21Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 20fludarabine phosphate 18Gemtuzumab 13Antilymphocyte Serum 12tipifarnib 11Radiotherapy 11Gene Expression Profiling 10Flow Cytometry 10Cyclosporine 10Clofarabine 10sargramostim 9Methotrexate 9Azacitidine 8aldesleukin 6Vorinostat 6Topotecan 6Tacrolimus 6valspodar 5alvocidib 5Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Megakaryoblastic, Acute × ixazomib × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡